Abstract:BackgroundAlzheimer’s disease (AD) causes progressive loss of memory and cognition, exacerbated by APOE4, the greatest genetic risk factor for AD. One proposed mechanism for apolipoprotein E (apoE) effects on cognition is via NMDAR-dependent signaling. APOE genotype-specific effects on this pathway were dissected using EFAD-transgenic (Tg) mice (5xFAD mice, that over-express human amyloid-beta (Aβ) via 5 familial-AD (FAD) mutations, and express human apoE), and 5xFAD/APOE-knockout (KO) mice. Previous data from EFAD-Tg mice demonstrate age-dependent (2-6 months), apoE-specific effects on the development of Aβ pathology. This study tests the hypothesis that apoE4 impairs cognition via modulation of NMDAR-dependent signaling, specifically via a loss of function by comparison of E4FAD mice with 5xFAD/APOE-KO mice, E3FAD and E2FAD mice.ResultsUsing female E2FAD, E3FAD, E4FAD and 5xFAD/APOE-KO mice aged 2-, 4-, and 6-months, the Y-maze and Morris water maze behavioral tests were combined with synaptic protein levels as markers of synaptic viability. The results demonstrate a greater age-induced deficit in cognition and reduction in PSD95, drebrin and NMDAR subunits in the E4FAD and 5xFAD/APOE-KO mice compared with E2FAD and E3FAD mice, consistent with an apoE4 loss of function. Interestingly, for NMDAR-mediated signaling, the levels of p-CaMK-II followed this same apoE-specific pattern as cognition, while the levels of p-CREB and BDNF demonstrate an apoE4 toxic gain of function: E2FAD > E3FAD > 5xFAD/APOE-KO > E4FAD.ConclusionThese findings suggest that compared with E2FAD and E3FAD, E4FAD and 5xFAD/APOE-KO mice exhibit enhanced age-induced reductions in cognition and key synaptic proteins via down-regulation of an NMDAR signaling pathway, consistent with an apoE4 loss of function. However, levels of p-CREB and BDNF, signaling factors common to multiple pathways, suggest a gain of toxic function. Publications in this field present contradictory results as to whether APOE4 imparts a loss or gain of function. As with the results reported herein, the overall effect of APOE4 on a given CNS-specific measure will be the product of multiple overlapping mechanisms. Thus, caution remains critical in determining whether APOE gene inactivation or therapies that correct the loss of positive function related to apoE4, are the appropriate therapeutic response.

APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's Disease pathology

The Genetic Risk Effects of APOE Ε4 and Novel Variants on Chinese Familial and Sporadic AD.

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation

The ε4‐bearing TOMM40‐APOE‐APOC1 haplotype but not the ε4 allele confers an exceptionally high risk of Alzheimer’s disease

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGF-mediated checkpoints

APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

Multifaceted roles of APOE in Alzheimer disease

A Loss of Function Variant in CASP7 Protects Against Alzheimer's Disease in Homozygous APOE Ε4 Allele Carriers.

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints

Non-coding Variability at the APOE Locus Contributes to the Alzheimer’s Risk

A multi‐hit hypothesis for an APOE4‐dependent pathophysiological state

Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience

The effects of APOEe4 allele on cerebral structure, function, and related interactions with cognition in young adults

Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer’s Disease Spectrum

TOMM40 and APOC1 variants differentiate the impacts of the APOE ε 4 allele on Alzheimer's disease risk across sexes, ages, and ancestries

Prevalence Of The Apolipoprotein E Epsilon 4 Allele In Amyloid Beta Positive Subjects Across The Spectrum Of Alzheimer'S Disease

The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease

APOEε4 and risk of Alzheimer's disease – time to move forward

APOE loss of function: A genetic shield against Alzheimer's disease

APOE4 Impairs Microglia ‐ Astrocyte Crosstalk in Alzheimer Disease